NCT02839889View on ClinicalTrials.gov

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

PHASE4TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

January 11, 2018

Study Completion Date

January 11, 2018

Conditions
CancerConstipationPain
Interventions
DRUG

Naloxegol

Naloxegol 25mg tablets for two weeks, followed by a two week open-label period

DRUG

Placebo

Placebo once daily for two weeks, followed by two week open-label period

Trial Locations (3)

10006

MJHS Institute for Innovation in Palliative Care, New York

28731

Hospice of Henderson County, Inc, Flat Rock

44110

Hospice of the Western Reserve, Inc., Cleveland

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Hospice of Henderson County, Inc.

OTHER